Is Calix a biotech stock? Today's Investor Presentation confirms that it is.
Set to become a multi-faceted conglomerate, Calix is claiming key territory in the hospital space - an ability to suppress golden staph and e-coli scourges by >90%.
A check of Slide 44 gives a glimpse of the group's plans. We're looking at a longer term strategy that may result in submissions to the FDA.
In the shorter term, discovery, development and possible partnering promises a steady, biotech-related news flow.
Calix claims >90% win over Golden Staph
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.020(1.87%) |
Mkt cap ! $197.9M | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.07 | $188.8K | 173.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17273 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 2592 | 1 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| CXL (ASX) Chart |